These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28423544)

  • 1. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
    Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
    Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
    Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
    Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
    Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
    Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
    Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
    Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
    Lanic H; Mareschal S; Mechken F; Picquenot JM; Cornic M; Maingonnat C; Bertrand P; Clatot F; Bohers E; Stamatoullas A; Leprêtre S; Rainville V; Ruminy P; Bastard C; Tilly H; Becker S; Vera P; Jardin F
    Leuk Lymphoma; 2012 Jan; 53(1):34-42. PubMed ID: 21806349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
    Jabłońska J; Jesionek-Kupnicka D; Potemski P; Kowalik A; Sygut J; Kordek R
    Pol J Pathol; 2010; 61(3):124-32. PubMed ID: 21225494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Song MK; Chung JS; Shin DH; Seol YM; Shin HJ; Choi YJ; Cho GJ
    Leuk Lymphoma; 2009 Jan; 50(1):54-61. PubMed ID: 19152170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Leppä S
    Mod Pathol; 2009 Aug; 22(8):1094-101. PubMed ID: 19448593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.
    Hong J; Park S; Park J; Kim HS; Kim KH; Ahn JY; Rim MY; Jung M; Sym SJ; Cho EK; Shin DB; Lee JH
    Leuk Lymphoma; 2011 Oct; 52(10):1904-12. PubMed ID: 21718130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
    Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
    Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence of germinal center B-cell-like and non-germinal center B-cell-like types of diffuse large B-cell lymphoma in Shanghai, China].
    Chen Y; Chen H; Fu K; Zhu XZ; Irons R
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):313-8. PubMed ID: 20654154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [State of chromosome 3q27 and different subtypes of diffuse large B-cell lymphoma and their prognostic correlation].
    Li Y; Wang GP; Xi YF; Wang JF; Bai W
    Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):231-6. PubMed ID: 19575893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
    Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A
    J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.